Hemolytic disease of the fetus and newborn (HDFN), a condition caused by maternal alloantibodies attacking fetal red blood cells, may be effectively managed with plasmapheresis, which reduced the need for intrauterine transfusions and improved neonatal outcomes, according to a study published recently in Reproductive, Female, and Child Health.
Despite variations in treatment protocols, plasmapheresis’s application in early pregnancy has been associated with favorable perinatal results. However, additional research is necessary to optimize therapeutic strategies and confirm these findings.
HDFN results from maternal alloantibodies crossing the placenta, leading to fetal red blood cell destruction. Severe cases can cause anemia, hydrops fetalis, and intrauterine fetal demise. This review analyzed 46 studies involving 208 pregnancies complicated by severe alloimmunization, assessing the effectiveness and safety of plasmapheresis. Among these cases, intrauterine fetal demise occurred in 22.1%, with one neonatal death. However, 77.4% of neonates had favorable postnatal outcomes, though most required phototherapy, and some required red blood cell transfusions.
“Plasmapheresis during pregnancy could be an effective therapy for severe Rhesus incompatibility. It can be initiated earlier in pregnancy and may help avoid or delay the need for intrauterine transfusions, particularly when combined with immunoglobulin therapy,” explained the authors of this study. They continued, “Although limited by the small number of cases included, the preliminary results of this review emphasise the significance of plasmapheresis in managing these cases and demonstrating its potential efficacy.”
Read more about treatment and care for HDFN
Plasmapheresis was initiated as early as three weeks’ gestation in some protocols, demonstrating its role in delaying or reducing the need for intrauterine transfusions in cases of severe fetal anemia. In the last decade, its use in combination with intravenous immunoglobulin (IVIG) has increased, enhancing maternal and neonatal outcomes. Treatment regimens varied significantly, with some protocols administering plasmapheresis every one to two weeks until delivery, while others limited it to three sessions. The volume exchanged also ranged widely, from 800 mL to 18 L per session.
The primary mechanism for assessing effectiveness of treatment involved monitoring antibody titres and fetal anemia through serial Doppler ultrasound of the middle cerebral artery. Earlier studies relied on measurements of amniotic fluid bilirubin, though this method has largely been replaced. Advances in neonatal care and improved techniques for intrauterine transfusion have contributed to better survival rates and reduced complications. Despite these improvements, plasmapheresis remains a valuable option, particularly before 20 weeks of gestation, when intrauterine transfusion is riskier.
The integration of IVIG therapy with plasmapheresis has demonstrated promising outcomes, potentially mitigating antibody rebound and reducing placental transfer of harmful alloantibodies. While its exact role and optimal administration protocol remain subjects of debate, current evidence supports its safety and efficacy. Continued investigation is warranted to refine treatment guidelines, determine ideal initiation timing, and establish standardized protocols for maximizing maternal and fetal well-being.
Overall, plasmapheresis offers a viable intervention for severe Rhesus alloimmunization, improving perinatal outcomes and reducing fetal transfusion requirements. Although further studies are needed, current evidence suggests that combining plasmapheresis with IVIG enhances safety and efficacy, positioning it as a critical tool in managing high-risk pregnancies.
Sign up here to get the latest news, perspectives, and information about HDFN sent directly to your inbox. Registration is free and only takes a minute.
